BAJAJ BROKING

Notification
No new Notification messages
NAPS Global India IPO is Open!
Apply for the NAPS Global India IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Dr Reddy’s Sells 14-Drug Portfolio to Senores Pharma for US Market Growth

Synopsis:

Dr Reddy’s Laboratories Ltd has sold 14 ANDAs to Senores Pharmaceuticals for an undisclosed amount. The portfolio, valued between $421 million and $1.13 billion in the US market, includes FDA-approved controlled substances and general drugs. Dr Reddy share price remained flat at ₹11,120.15.


Dr Reddy’s Laboratories Ltd has finalised an agreement to sell a portfolio of 14 Abbreviated New Drug Applications (ANDAs) to Ahmedabad-based Senores Pharmaceuticals Ltd. The acquisition, funded by Senores’ recent IPO proceeds of ₹5.82 billion, will help the company expand its presence in the regulated US market. The financial terms of the deal have not been disclosed.

Also read: Welspun Specialty Wins ₹231.77 Crore BHEL Contract for Boiler Tubes

DR. REDDY S LABORATORIES

Trade

1133.25-6.84 (-0.59 %)

Updated - 07 March 2025
1145.20day high
DAY HIGH
1130.00day low
DAY LOW
790599
VOLUME (BSE)

Key Takeaways:

  • Number of ANDAs Sold: 14 (13 FDA-approved, 1 pending approval)

  • US Market Valuation: Estimated between $421 million and $1.13 billion

  • Acquirer: Senores Pharmaceuticals Ltd

  • Funding Source: ₹5.82 billion IPO proceeds from December

  • Product Categories: Controlled substances and general category drugs

  • Market Focus: US, with growth potential in other regulated and semi-regulated markets

Also read: Power Grid Wins Bids for 3 Interstate Transmission Projects Under BOOT Model

Portfolio Overview and Market Potential

The 14 ANDAs acquired by Senores Pharma include controlled substances and general drugs that cater to various healthcare segments, including government procurement, retail chains, and specialty clinics. The total addressable market for these drugs in the US is projected to be between $421 million and $1.13 billion.

The acquisition is expected to strengthen Senores’ footprint in the US pharmaceutical market while complementing its expansion strategy in other regulated territories. The company plans to leverage its manufacturing and distribution network to maximise market penetration.

Transaction Details

Information

Number of ANDAs

14 (13 FDA-approved, 1 pending)

Estimated US Market Value

$421 million - $1.13 billion

Acquirer

Senores Pharmaceuticals Ltd

Funding Source

₹5.82 billion IPO proceeds

Product Categories

Controlled substances, generics

Target Markets

US, regulated, and semi-regulated markets

Market Reaction and Dr Reddy Share Price Performance

Following the announcement, Dr Reddy share price remained nearly flat, closing at ₹11,120.15 on the National Stock Exchange (NSE). Meanwhile, Senores Pharmaceuticals’ stock surged 6.03% to ₹562.50, reflecting investor optimism about the company’s expansion in the US pharmaceutical market.

Dr Reddy’s Laboratories Ltd’s sale of its 14-drug portfolio to Senores Pharma highlights its strategic shift in portfolio management. The transaction allows Senores Pharma to expand in the US market while Dr Reddy share price remained steady. The completion of regulatory approvals will determine the impact of this deal on both companies in the coming months.

Also read: Apollo Hospitals Invests ₹250 Crore in India’s First Proteus One System

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9 lakh+ Users

icon-with-text

4.3+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300+ Cr MTF Book

icon-with-text